Respiratory Syncytial Virus (RSV) is a common respiratory virus that can cause serious illness in vulnerable groups, including older adults, infants and young children.
In 2026, both the National Immunisation Program (NIP) and Victorian Government are providing expanded access to RSV immunisation programs designed to help protect those most at risk of severe RSV disease.
The latest updates include funded RSV vaccination programs for eligible older adults, pregnant women and infants.
Free RSV Vaccination for Eligible Older Adults
A single dose of the Arexvy® RSV vaccine is now available free under the National Immunisation Program for:
- Adults aged 75 years and over
- Aboriginal and Torres Strait Islander adults aged 60 years and over
RSV can lead to serious respiratory illness, particularly in older adults and those with underlying medical conditions. Vaccination may help reduce the risk of severe RSV-related illness and hospitalisation.
Adults aged 60 to 74 years who are not eligible under the National Immunisation Program may still be able to access RSV vaccination through private purchase after discussing suitability with their healthcare provider.
RSV Vaccination During Pregnancy
The Abrysvo® RSV vaccine is available year-round under the National Immunisation Program for pregnant women.
Vaccination is recommended during each pregnancy from 28 weeks gestation to help protect newborn infants from RSV during the first months of life.
Protective antibodies generated following vaccination are transferred from mother to baby during pregnancy, helping provide passive protection after birth.
Key points include:
- Recommended during each pregnancy
- Can be administered from 28 weeks gestation
- Protection is transferred to the baby before birth
- May provide protection for infants during the first six months of life
Pregnant women should speak with their doctor about whether RSV vaccination is appropriate for them.
Infant RSV Immunisation Program
The Victorian Government-funded infant RSV immunisation program is operating from mid-March to 30 September 2026.
The program provides Beyfortus™ (nirsevimab), a long-acting monoclonal antibody, for eligible infants and young children at increased risk of severe RSV disease.
It is important to note that:
- Abrysvo® and Arexvy® are not approved for use in infants or children
- Beyfortus™ (nirsevimab) is the approved product used for eligible infants and young children
Eligibility criteria apply and parents should speak with their healthcare provider for further information.
Why RSV Protection Is Important
RSV is a highly contagious respiratory virus that affects people of all ages. While many people experience mild symptoms, RSV can cause more serious illness in:
- Older adults
- Newborns and infants
- Young children
- People with certain underlying health conditions
Each year RSV contributes to significant numbers of medical presentations and hospitalisations across Australia.
Vaccination and immunisation programs are designed to help reduce the burden of severe RSV disease among higher-risk groups.
Where to Find More Information
The Victorian Department of Health has published detailed information for healthcare providers regarding RSV immunisation programs, vaccine eligibility and clinical guidance.
You can also discuss RSV vaccination eligibility with your GP during your next appointment.
View Official RSV Immunisation Information
Speak With Your GP About RSV Vaccination
If you are aged 75 years or older, are pregnant, or are caring for an infant who may be eligible for RSV protection, speak with your GP about the available RSV immunisation programs.
Hampstead Medical provides comprehensive healthcare services for individuals and families and can help patients understand current vaccination recommendations and eligibility requirements.